Trial Profile
Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Therapeutic Use
- 28 Sep 2022 Status changed from active, no longer recruiting to completed.
- 03 Feb 2022 Planned End Date changed from 1 Dec 2020 to 1 Dec 2023.
- 20 Nov 2019 Planned End Date changed from 1 Feb 2020 to 1 Dec 2020.